Holen Sie sich die Stockscreener-App
0.6657
8.08%
0.0567
Schlusskurs vom Vortag:
$0.609
Offen:
$0.615
24-Stunden-Volumen:
6.78M
Relative Volume:
0.26
Marktkapitalisierung:
$161.55M
Einnahmen:
$424.90K
Nettoeinkommen (Verlust:
$-94.02M
KGV:
-0.268
EPS:
-2.4842
Netto-Cashflow:
$-51.25M
1W Leistung:
-5.97%
1M Leistung:
-53.15%
6M Leistung:
+49.69%
1J Leistung:
-77.84%
1-Tages-Spanne:
$0.6115
$0.6675
1-Wochen-Bereich:
$0.59
$0.7181
52-Wochen-Spanne:
$0.1611
$3.39
Outlook Therapeutics Inc Stock (OTLK) Company Profile
Firmenname
Outlook Therapeutics Inc
Sektor
Branche
Telefon
(609) 619-3990
Adresse
111 S. WOOD AVENUE, ISELIN, NJ
Compare OTLK vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OTLK
Outlook Therapeutics Inc
|
0.6657 | 164.12M | 424.90K | -94.02M | -51.25M | -2.4842 |
VRTX
Vertex Pharmaceuticals Inc
|
552.69 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
836.19 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,021.84 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
156.79 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
212.49 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-29 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-08-28 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-12-02 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2024-03-27 | Hochstufung | BTIG Research | Neutral → Buy |
| 2024-02-15 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2024-01-25 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-12-27 | Hochstufung | CapitalOne | Equal Weight → Overweight |
| 2023-08-31 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2023-08-31 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-08-30 | Herabstufung | BTIG Research | Buy → Neutral |
| 2023-08-30 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-08-30 | Herabstufung | CapitalOne | Overweight → Equal Weight |
| 2023-08-30 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-07-13 | Eingeleitet | CapitalOne | Overweight |
| 2023-04-03 | Eingeleitet | Guggenheim | Buy |
| 2023-02-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-10-31 | Eingeleitet | BTIG Research | Buy |
| 2022-09-13 | Eingeleitet | Chardan Capital Markets | Buy |
| 2019-09-11 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2019-05-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-04-22 | Eingeleitet | Ascendiant Capital Markets | Buy |
Alle ansehen
Outlook Therapeutics Inc Aktie (OTLK) Neueste Nachrichten
OTLK Stock Soars 28% After FDA Sets July Date For Lytenava Decision - Stocktwits
OTLK Stock Surges On FDA Lytenava Application Resubmission After Successful Appeal - Stocktwits
OTLK Stock Rocket Nearly 140%: FDA's Lytenava FDR Approval Pushes Stock On Track For Best Week On Record - Stocktwits
Outlook Therapeutics(OTLK) Stock Options Chain | Quotes & News - Moomoo
Nasdaq Futures Lead US Premarket Rally As Iran Ceasefire Reports Ease Fears Ahead Of Big Tech Earnings: Why NVDA, ORCL, SPCX, XOM, OTLK Are In Focus - Stocktwits
Outlook Therapeutics Inc (OTLK) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Outlook Therapeutics, Inc. 2026: Revenue $8.7K, EPS ($0.15) — 10-Q Summary - TradingView
Outlook Therapeutics (OTLK) wins FDA exclusivity but holds limited cash - Stock Titan
Brookline Capital cuts Outlook Therapeutics stock price target on model update - Investing.com
These 3 Stocks Led Wall Street’s Biggest Gains On Tuesday – Here’s Why - Stocktwits
Outlook Therapeutics delays quarterly SEC filing - TipRanks
META_TITLE_QUOTE - Yahoo Finance
OTLK Q3 Earnings Call Maps LYTENAVA U.S. Launch and Sales Ramp - Yahoo Finance
Outlook Therapeutics Insider Bought Shares Worth $2,499,999, According to a Recent SEC Filing - moomoo.com
Outlook Therapeutics delays Q2 Form 10-Q filing after finance staff turnover - Bitget
Outlook Therapeutics Posts Q3 Financials, Raises Funds for Lytenava Launch - VisionMonday.com
symbol__ Stock Quote Price and Forecast - CNN
Outlook Therapeutics Inc (OTLK) Stock News Today - TradingKey
MSN Money - MSN
Outlook Therapeutics CEO Robert Jahr acquires shares and warrants for $0 - Investing.com South Africa
Outlook Therapeutics (OTLK) Stock May Be No Bargain With Approval But Weak Balance Sheet - Yahoo Finance
Outlook Therapeutics (OTLK) Stock Looks Fully Valued While Book Value Stays Unclear - simplywall.st
Outlook Therapeutics CFO Kenyon acquires 101,010 shares By Investing.com - Investing.com South Africa
Outlook Therapeutics (OTLK) CEO purchases 151,515 shares and matching warrants - Stock Titan
Outlook Therapeutics, Inc. 2026 Q3ResultsEarnings Call Presentation (NASDAQ:OTLK) 2026-08-14 - Seeking Alpha
Outlook Therapeutics director Ghiath Sukhtian buys $2.5m in shares By Investing.com - Investing.com Australia
Outlook Therapeutics director Ghiath Sukhtian buys $2.5m in shares - Investing.com
Outlook Therapeutics CFO Kenyon acquires 101,010 shares - Investing.com
Outlook Therapeutics (OTLK) investor GMS Ventures reports 16.4% beneficial stake - Stock Titan
Outlook Therapeutics (OTLK) insider-linked entity buys 2.5M shares plus 2.5M warrants - Stock Titan
Outlook Therapeutics (OTLK) CFO Lawrence Kenyon buys 101K shares plus 101K warrants - Stock Titan
Outlook Therapeutics Stock Price Forecast. Should You Buy OTLK? - StockInvest.us
OTLK Q3 FY2026 earnings call - finance.biggo.com
Outlook Therapeutics to Report Q3 After $55 Million Stock Sale Sends Shares Tumbling - finance.biggo.com
Friday's session: most active stocks - ChartMill
OTLK Reiterated by BTIG -- Price Target Maintained at $4.00 - GuruFocus
Oncobiologics Q3 Earnings Call Highlights - MarketBeat
Earnings call transcript: Outlook Therapeutics narrows loss in Q3 2026 as launch nears - Investing.com
Outlook Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
OTLK: FDA-approved LYTENAVA targets rapid U.S. launch and $500M+ peak sales by 2030 - TradingView
Outlook Therapeutics Announces $55 Million Equity Offering - TipRanks
Transcript: Outlook Therapeutics Q3 2026 Earnings Conference Call - Benzinga
Outlook Therapeutics, Inc. (OTLK) Stock Forecasts - Yahoo! Finance Canada
Outlook Therapeutics (OTLK) Q3 Earnings Miss Highlight Valuation Challenges - GuruFocus
Q3 2026 Outlook Therapeutics Inc Earnings Call Transcript - GuruFocus
Form 8K OUTLOOK THERAPEUTICS INC For: 14 August By Investing.com - Investing.com Nigeria
Outlook Therapeutics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
Finanzdaten der Outlook Therapeutics Inc-Aktie (OTLK)
Umsatz
Nettogewinn
Free Cashflow
ENV
Outlook Therapeutics Inc-Aktie (OTLK) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Sukhtian Faisal Ghiath | Director |
Jul 29 '26 |
Buy |
1.05 |
95,398 |
99,996 |
220,972 |
| Haddadin Yezan Munther | Director |
Jun 02 '26 |
Buy |
0.83 |
29,000 |
24,145 |
66,167 |
| Sukhtian Ghiath M. | Director |
May 28 '26 |
Buy |
0.59 |
8,539,709 |
5,000,000 |
22,092,068 |
| Sukhtian Faisal Ghiath | Director |
May 27 '26 |
Buy |
0.41 |
122,174 |
50,006 |
125,574 |
| Haddadin Yezan Munther | Director |
May 26 '26 |
Buy |
0.44 |
34,000 |
14,960 |
37,167 |
| THURMAN RANDY H | Director |
May 26 '26 |
Buy |
0.43 |
5,000 |
2,145 |
5,593 |
| HILZINGER KURT J | Director |
May 26 '26 |
Buy |
0.44 |
400,000 |
176,520 |
423,655 |
1.66%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):